Retinal gene therapy holds great promise for the treatment of inherited and noninherited blinding diseases such as retinitis pigmentosa and age-related macular degeneration. The most widely used vectors for ocular gene delivery are based on adeno-associated virus (AAV) because they elicit minimal immune responses and mediated long-term transgene expression in a variety of retinal cell types. Extensive preclinical evaluation of new strategies in large animal models is key to the development of successful gene-based therapies for the retina. Because of differences in the retinal structures among species and unique structures such as the macula and fovea in the primate retina, nonhuman primates are widely used as preclinical animal models. But the observation of inherited retinal degenerations in dogs, which share a number of clinical and pathologic similarities with humans, has led to the characterization of several canine models for retinal diseases, one of which has already responded successfully to AAV-mediated gene therapy. This article presents a review and detailed discussion of the various large animal models available for the study of AAV-mediated gene-based therapies in the retina.
Introduction

S
ignifi cant progress in understanding the molecular basis of a variety of retinal disorders has led to the development of gene therapies for treatment of these diseases. Of all the vectors that have been evaluated in the eye, recombinant adeno-associated virus (rAAV 1 ) is potentially the most useful for the treatment of retinal diseases as its tropism and transduction patterns lead to effi cient and stable gene transfer in a variety of retinal cell types. The retinal diseases that have been studied for suitability of genebased therapies include retinal degenerative diseases, such as retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA), and neovascular diseases, such as age-related macular degeneration (AMD 1 ), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
Recombinant AAV-mediated gene therapy studies have involved gene transfer to spontaneous as well as transgenic animal models of the diseases. Evaluation of rAAV-mediated gene transfer in the eye of large animals is highly relevant to clinical development as large animals' eyes are anatomically more similar to the human eye than those of mice or rats. Retinal degenerative diseases occur naturally in the canine and feline population, and large animal models for retinal neovascular disorders have been generated in pigs and nonhuman primates, but only dogs and nonhuman primates have been the subject of experimental studies for the development of adeno-associated viral (AAV 1 )-mediated gene therapy. 2 The nonhuman primate in particular has ocular anatomic features virtually identical to those of humans (including the macula) and its components are of similar proportion. Moreover, surgical procedures for vector delivery and the amount of injected vector for primates are similar to those for humans. In addition, primates' immunological and biological similarity to humans is essential for determining tolerance to vectors before clinical trials. However, there are no naturally occurring models for inherited retinal dystrophies in nonhuman primates.
The fact that many human genetic diseases have their equivalent in the canine population allows for the evaluation of gene therapy in dogs affected by diseases that mimic their human counterpart. For example, close similarities in the clinical characteristics of the disease resulting from RPE65 gene mutations (mutations in the gene encoding the retinal pigment epithelium [RPE 1 ]-specifi c 65-kDa protein) make the RPE65 −/− Briard dog a valuable model for the evaluation of gene therapy for this disease. Indeed, after extensive evaluation in RPE65 −/− dogs, gene therapy for inherited retinal degeneration due to RPE65 defi ciency is now being tested in three concurrent clinical trials.
For all these reasons, nonhuman primates and canine models of retinal diseases are key tools to develop and evaluate gene transfer as a treatment. In this article we provide an overview of retinal degenerative and neovascular disorders in humans and review the current large animal models for retinal AAV-mediated gene therapy, their applications, their great intrinsic value, and their potential to facilitate the clinical translation of fi ndings.
Retinal Disorders in Humans
In this fi rst section we provide an overview of the different retinal degenerative and neovascular disorders in humans that may be suitable for potential gene-based therapies.
Retinal Degenerative Disorders
Retinitis Pigmentosa (RP) There are three groups of hereditary degenerative disorders of the retina, based on which type of photoreceptor manifests the primary insult, rods or cones. The three types of disorder are rod-cone dystrophies (retinitis pigmentosa, RP 1 ), cone-rod dystrophies (inverse RP), and cone dystrophies (maculopathies). Visual symptoms for all three indicate the gradual loss of the two photoreceptor types: rods, which mediate achromatic vision under poor lighting conditions; and cones, which are important for color vision and visual acuity in daylight. In this section we focus on the fi rst two types.
RP has a worldwide prevalence of 1 in 4000 people, leading to 1 million total affected individuals worldwide (Berson 1993; Hartong et al. 2006; Puech et al. 1991) . One in ten cases is inverse RP.
The onset of RP can vary signifi cantly: some patients lose vision very early in life whereas others remain asymptomatic until midadulthood (Hartong et al. 2006) . All RP patients eventually develop diffi culties with dark adaptation and night blindness and subsequently loss of midperipheral visual fi eld. Patients with inverse RP rapidly lose central vision and develop abnormalities of color vision associated with a variable degree of nystagmus and photophobia. Over time, rod system abnormalities lead to impaired peripheral vision (Michaelides et al. 2006; Rabb et al. 1986 ).
Most cases of RP are monogenic, but the disease itself is very heterogeneous. Researchers have associated about 200 loci with retinal dystrophies, and identifi ed and characterized about 45 genes that cause RP 3 (Hartong et al. 2006 ). Interestingly, these 45 genes collectively account for only a little over half of all patients. There are three predominant modes of inheritance of RP: autosomal recessive (50-60%), autosomal dominant (30-40%), and X-linked (5-15%) (Hartong et al. 2006) . Other forms of inheritance, such as uniparental isodisomy or non-Mendelian inheritance (mitochondrial or digenic), occur only very rarely. Most genes cause only a small proportion of cases, but there are some exceptions; for example, the RHO gene causes about 25% of autosomal dominant RP cases, the USH2A gene causes 20% of autosomal recessive cases, and RPGR causes 70% of X-linked cases. Mutations in these three genes account for about 30% of all RP cases (Hartong et al. 2006) .
The roles of the proteins encoded by many of these genes have been deciphered recently, and knowledge of the molecular function may help researchers to better understand the pathways that lead to photoreceptor degeneration and visual loss. These proteins are involved in the visual cycle that includes the phototransduction cascade and the retinoid cycle. Other proteins are structural or cytoskeletal proteins, while still others are signaling proteins, transport and traffi cking proteins, transcription factors, and proteins involved in phagocytosis and pH regulation (Hartong et al. 2006) . Although these proteins are involved in a variety of biochemical pathways, mutations in one of the corresponding genes eventually leads to degeneration of the retina due to loss of photoreceptors. The mechanisms by which the genetic defects lead to photoreceptor cell death are still not clearly understood, but recent advances shed light on some of them. The fi nal pathway in all cases is apoptosis (Marigo 2007) .
Leber Congenital Amaurosis (LCA)
Leber congenital amaurosis (LCA 1 ) is the most severe form of all hereditary retinal dystrophies and is responsible for congenital blindness, with an estimated prevalence of about 5% of all cases of RP (Kaplan et al. 1990; Koenekoop 2004) . Symptoms include severe impairment of visual function at birth or within the fi rst months of life. In infants, these signs include the inability to visually fi x on objects, nystagmus, a diminished photomotor refl ex, and the presence of the oculodigital Franceschetti sign. The funduscopic image of such patients is normal and the electroretinogram (ERG 1 ) nonrecordable (Koenekoop 2004) .
LCA is a genetically heterogeneous condition. In most cases the inheritance pattern is autosomal recessive, although some autosomal dominant mutations are known. To date, 14 genes are known to contribute to the onset of the disease: IMPDH1, AIPL1, CRB1, CEP290, CRX, GUCY2D, LCA5, LRAT, MERTK, RD3, RDH12, RPGRIP1, TULP1, and RPE65. Mutations in these genes account for about 70% of all cases of LCA, thus many genes responsible for the onset of this disease remain undiscovered (den Hollander et al. 2008) .
The identifi ed genes have important roles in several different biochemical pathways in the retina and also cause some forms of RP. The same mechanisms of photoreceptor cell death seen in RP also lead to retinal degeneration in LCA, and their common fi nal pathway is, as mentioned above, apoptosis (Marigo 2007) .
Retinal Neovascular Disorders
Age-Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is the largest single cause of severe visual impairment in individuals over 50 years of age worldwide, and its prevalence continues to increase. This disease is diagnosed in 2% of the population between the ages of 45 and 65, in 12% of those aged 65 to 75, and in 30% of individuals older than 75 (Friedman et al. 2004; Klein et al. 1992) .
Recent etiological research has shown that AMD most likely results from interactions of multiple genes and environmental factors (Chamberlain et al. 2006; Donoso et al. 2006; Haddad et al. 2006) . The most well-established demographic and environmental risk factors are increasing age and cigarette smoking (Klaver et al. 2001; Klein et al. 2007; Tomany et al. 2004; Wang et al. 2007) ; fat intake and obesity also play a role. Protective effects have been associated with antioxidants, nuts, fi sh, and omega-3 fatty acids (Seddon et al. 1994 (Seddon et al. , 2003 . Recent fi ndings showed a strong association of the complement factor H (CFH) with the onset of AMD (Edwards et al. 2005; Haines et al. 2005; Klein et al. 2005) . One single nucleotide polymorphism, Tyr402His in the CFH gene, is linked to about 50% of all cases of AMD. As this factor is found in drusen, and all complement factors are generally upregulated during smoking, the role of infl ammation in the pathogenesis of AMD may be important.
There are two types of AMD: the atrophic form, called "dry" AMD, and the exudative form, called "wet" AMD (Bird et al. 1995) . Typical clinical signs of the atrophic form of the disease are drusen, pigmentary changes, pigmentary epithelial defects, disciform scarring, and geographic atrophy. The dry form occurs in patients at the beginning of the disease and can later develop into the wet form, which is characterized by choroidal neovascularization (CNV 1 ), hemorrhage, and retinal detachment. Although only 10% of all patients develop the wet form of the disease, they account for most cases of severe visual loss (Ambati et al. 2003; Ferris et al. 1984) . Patients affected with both forms of AMD have metamorphopsia, loss of visual acuity, and color vision problems because the pathologic changes are mostly apparent in the macula region of the retina. These symptoms profoundly affect patients in their daily life as they lose the ability to read, write, and drive.
Choroidal neovascularization during the wet form of the disease is due to a change in the balance of growth factors in the eye that regulate the vascularization of the choroid and the retina (Campochiaro 2000; Holz et al. 2004) . How this balance is changed is not exactly known, but one hypothesis cites hypoxic conditions due to a thickening of the Bruch's membrane (Green and Enger 1993; Grunwald et al. 1998 ).
Another suggests that infl ammation plays a role in the onset of CNV (Ryan 1982) ; material found in drusen, and the recent discovery that a specifi c complement factor H polymorphism is a risk factor for CNV, seem to confi rm this theory (Donoso et al. 2006) . In all cases, damage to the Bruch's membrane leads to the growth of new vessels into the ruptured site and the concomitant proliferation and thickening of the retinal pigment epithelium (Campochiaro 2000) .
The most important growth factors in the retina are vascular endothelial growth factor (VEGF 1 ) and pigment epithelium-derived factor (PEDF) (Ferrara and Kerbel 2005; Witmer et al. 2003) . Other factors that regulate neovascularization are angiopoietins (proangiogenic factors) and angiostatins and endostatins (antiangiogenic factors). High concentrations of VEGF have been found in surgically resected choroidal neovascular membranes from AMD patients, indicating the importance of VEGF in the mechanisms that lead to CNV (Lopez et al. 1996) . PEDF is responsible for the suppression of inward growth of blood vessels from the choroid into the Bruch's membrane, thus keeping it nonvascular (Dawson et al. 1999; Eichler et al. 2004) .
Standard treatment includes argon laser photocoagulation and photodynamic therapy (PDT) (Chong and Bird 1998) . Increasing knowledge about the pathogenesis of CNV, especially the involvement of growth factors in the onset of new vessels, has facilitated the development (Ferrara and Kerbel 2005) and widespread use of a range of synthetic proteins to block new vessel growth in treatment protocols for this disease (Bashshur et al. 2006; Brown et al. 2006; Ng and Adamis 2006; Rosenfeld et al. 2006) .
Diabetic Retinopathy (DR)
Diabetic retinopathy (DR) accounts for about 5% of all visually impaired persons (almost 5 million people worldwide) and is the most common cause of vision impairment in working-age adults (20-65 years) (Klein et al. 1992) . Twenty percent of all patients with diabetes mellitus will develop retinal neovascularization, the major cause of vision loss in this disease.
Patients with DR experience central vision loss and impaired peripheral vision. The disease is a progressive, microvascular complication of diabetes mellitus that causes damage to retinal capillaries (Ting and Martin 2006) . The complication, termed microangiopathy, involves damage of the endothelial cells lining the retinal blood vessels and pericytes, resulting in microaneurysms and the subsequent closure of blood vessels. This fi rst stage of the disease is nonproliferative DR, in which clogged retinal blood vessels lead to ischemia in the surrounding tissue. This results in retinal neovascularization (RNV), which is the next stage of the disease, now called proliferative DR. The newly formed vessels, weak and prone to damage, eventually rupture, causing hemorrhage and macular edema (Campochiaro 2000; Kent et al. 2000) . In addition, contraction of fi brovascular proliferations in the retina may cause retinal detachment (Frank 2004; Ting and Martin 2006) . RNV results from both a hypoxia-induced increase in the expression levels of VEGF and insulin-like growth factor-1 (IGF-1) and a decrease in antiangiogenic factors such as PEDF (Aiello 2005; Ferrara and Kerbel 2005; Frank 2004 ). Animal studies using various VEGF inhibitors have directly demonstrated the role of VEGF as a key mediator of ischemia-induced retinal neovascularization in DR (Adamis et al. 1996; Aiello et al. 1995; Robinson et al. 1996) , and have described elevations of VEGF levels in the aqueous and vitreous humor of human eyes with DR (Aiello et al. 1994; Malecaze et al. 1994 ) and the upregulation of VEGFR-2 on endothelial membranes of retinal capillaries (Witmer et al. 2003) .
Recombinant AAV Gene Transfer in the Retina of Dogs and Nonhuman Primates
In this section we provide an overview of the basic mechanisms of AAV-mediated gene transfer, cellular tropism in the retina, and biodistribution of AAV vectors after retinal gene transfer in large animals. Studies in these areas are essential for the development of AAV-mediated gene therapy protocols, which we also describe below.
The generation of new information about these important aspects of viral vector-mediated gene transfer into the eye has depended on a variety of animal models, most of them genetically engineered mice (Auricchio and Rolling 2005; Buch et al. 2008) . But spontaneous mutations have led to retinal degenerations in dogs that have been thoroughly characterized and have served as animal models for gene therapy. Because of differences of retinal structures among species and unique structures (such as the macula and fovea) in the primate retina, nonhuman primates are also useful as preclinical animal models.
AAV as Vector for Gene Transfer into the Retina
Adeno-associated viruses are considered nonpathogenic, contain a single-stranded DNA genome, and are able to infect a variety of dividing and nondividing cells. These characteristics make AAV-derived vectors favorable for many applications in gene therapy, especially in the retina (Warrington and Herzog 2006) . AAVs belong to the family of Parvoviridae and are among the smallest known viruses, without envelope and approximately 19 to 21 nm (Siegl et al. 1985) . They were fi rst discovered as a small contaminating DNA virus in an adenovirus preparation about 40 years ago (Atchison et al. 1965) . The virus's single strand of DNA has about 4700 base pairs (bp 1 ), contains two open reading frames (ORFs 1 ) for the production of viral proteins, and is fl anked by two inverted terminal repeats (ITRs) necessary for viral replication (Flotte 2004; Srivastava et al. 1983) . To date, 12 serotypes have been identifi ed that display distinct binding and cell tropism characteristics, which are important when choosing the optimal vector for the transfer of genes into a specifi c tissue. In addition, the cellular tropism of serotypes varies among species.
To obtain a recombinant vector, the whole coding sequence of wild-type AAV DNA is replaced by an expression cassette containing a promoter sequence, the gene of interest, and a poly-A tail. Only the ITR sequences are necessary in cis for the production of the vector. The actual production technique for AAV vectors uses the ITRs of AAV2, which fl ank the expression cassette encapsidated in the viral capsids of the AAV serotype of choice. The method for the production of these chimeric vectors is called "cross packaging" and the corresponding AAV vectors are called AAV2/1, AAV2/2, and so forth (Rabinowitz et al. 2002) .
Cellular Tropism of rAAV Vectors
Different AAV serotypes display tissue preference and specifi c cellular tropism in a variety of organs. The retina contains many different cell types, some of them unique to the eye, so it is necessary to test the cellular tropism of each serotype in the retina of every animal model before starting any gene therapy protocol. Over the last decade, serotypes AAV2/1, 2/2, 2/3, 2/4, 2/5, and 2/6 have been tested for cellular tropism and long-term expression in the retina of rodents, dogs, and nonhuman primates. More recently, serotypes 7 to 9 have also been studied but, with the exception of serotype 8, have not passed the mouse level. In this section we focus on studies in large animals.
There are two methods of delivery of vector to the retina: intravitreal and subretinal injection. Intravitreal injection produces close contact of the vector with retinal ganglion cells, separated only by the hyaloid membrane; with subretinal injection, the needle is advanced through the vitreous and the tip positioned between the RPE and the photoreceptor layer, permitting the deposit of vectors directly adjacent to the cells of interest. The detachment of the neuroretina from the RPE, due to the volume of vector solution injected, resolves within 24 hours (Rolling, personal observation).
Only AAV serotype 2 transduces retinal (mainly ganglion) cells after intravitreal injection, but effi cacy of transduction and level of transgene expression have been low in rodents (Dudus et al. 1999; Folliot et al. 2003; Guy et al. 1999; Liang et al. 2001) , so this technique is not used in large animal models.
The cellular tropism of most AAV serotypes has been verifi ed after subretinal injection in rodent models, but only a few have been thoroughly characterized in large animals. Bainbridge and colleagues (2003) observed transgene expression in RPE and photoreceptor cells after subretinal injection of AAV2/2 vector in dogs. Comparative studies using AAV2/2 and AAV2/5 showed that the transduction effi cacy of photoreceptors by AAV2/5 was superior to that of AAV2/2 in rats, dogs, and nonhuman primates, and that AAV2/4 allowed exclusive and stable transduction of RPE cells in all three animal models (Weber et al. 2003) . Subretinal injection of a complete AAV5/5 showed higher transduction effi cacy than AAV2/2 in RPE and photoreceptors of mice and nonhuman primates (Lotery et al. 2003) .
Recently, the AAV serotype 8 has been used to study cellular tropism in rodents and dogs (Stieger et al. 2008) . In contrast to all other serotypes tested, subretinal delivery of AAV2/8 was able to transduce all cell layers in the retinathe RPE, photoreceptors, cells of the inner nuclear layer, and ganglion cells. Moreover, the expression of green fl uorescent protein (GFP 1 ) was not limited to the injected area, as has been the case with the other serotypes. Transgene expression was detectable in all cell layers outside the injected area. This observation may have important consequences for gene therapy trials, where widespread expression of the transgene in the retina is the objective.
Safety and Biodistribution of rAAV-Mediated Gene Transfer
Evaluation of the safety of gene transfer in the eye of large animal models is highly relevant for the development of future clinical trials. As mentioned above, nonhuman primates have ocular anatomic features similar in proportion and size to those in humans. In addition, surgical procedures for vector delivery and the amount of vector injected in dogs and primates are similar to those used in humans. Furthermore, dogs and especially primates have greater immunological and biological similarities to humans than do rodents, an essential feature for determining the tolerance of vectors before clinical trials.
As fl uorescence fundus photography has facilitated the direct visualization of GFP expression in the retina, vectors encoding this reporter gene have been used to study the capacity of AAV for long-term expression in the retina of large animals. Subretinal injection of an AAV2/2 vector carrying the GFP gene under the control of a cytomegalovirus (CMV) promoter in dogs resulted in effi cient and stable transgene expression for at least 18 months (Bainbridge et al. 2003) . Using the same vector in the primate retina led to effi cient transduction of RPE cells and rod photoreceptors for more than 12 months . Another study, using the AAV5 capsid and the expression cassette fl anked by the AAV5 ITRs (AAV5/5), showed similar cellular tropism in the primate retina and persistent transgene expression for 10 months, the duration of the study (Lotery et al. 2003) .
To evaluate the short-term morbidity of subretinal injections and the safety of long-term rAAV-mediated transgene expression, Le Meur and colleagues (2005) unilaterally injected AAV2/2, AAV2/4, and AAV2/5 in 14 beagle dogs and 9 nonhuman primates. They found that such injections in both species were safe, with no perioperative complications and a high rate of successful retinal gene transfer (95%). Angiography and electroretinography revealed that retinal anatomy and function remained unchanged, despite persistent transgene expression for up to 6 years.
A primary requirement for safe and successful ocular gene therapy with rAAV is an accurate evaluation of vector distribution after subretinal or intravitreal delivery-multiple cell types in the retina are exposed to the vector and some scattering of vector to the systemic circulation is possible, and because the eye is closely connected to the brain via the optic nerve it is important to check for the presence of vector DNA in the brain. Weber and colleagues (2003) documented vector shedding after subretinal delivery of rAAVs in dogs and nonhuman primates; they detected vector DNA in the serum and nasal and lacrimal fl uid of injected animals as early as 15 minutes after AAV administration and for up to 25 days (for the serum) and up to 4 days (for the nasal and lacrimal fl uid) in some individuals.
Regarding the distribution of vector DNA in the optic nerve and brain, investigators have to distinguish between the presence of transgene product and the actual expression of the transgene in the brain. Early studies showed that after intravitreal injection of AAV2/2.CMV.gfp in mice and dogs, levels of GFP protein persist for 6 months in the brain and optic nerve, but no vector DNA was detectable outside the retina (Dudus et al. 1999) . Other studies showed the presence of β-galactosidase and β-glucuronidase as transgene products in the optic nerve or the brain of mice and guinea pigs, respectively (Guy et al. 1999; Hennig et al. 2003) ; again, vector DNA was not present in the optic nerve or brain. Griffey and colleagues (2005) showed improved enzyme activity along the visual pathway in the brain after intravitreal delivery of an AAV2/2 vector encoding for the missing enzyme in a mouse model of infantile neuronal ceroid lipofuscinosis. Their data suggest that AAV2/2-mediated intravitreal gene transfer resulted in the transduction of retinal ganglion cells and that transgene products were anterogradely transported along the visual pathway into the brain; but they do not show any anterograde transport of vector DNA into the brain via the optic nerve.
In contrast, Provost and colleagues (2005) studied the vector DNA distribution in rats and, more importantly, in dogs and nonhuman primates after subretinal or intravitreal injection of AAV2/2, 2/4, and 2/5 vectors. They detected vector DNA occasionally in peripheral blood mononuclear cells at early time points after injection in all animals. Specifi cally, vector DNA sequences were present in the optic nerve of dogs and primates that received subretinal injections of AAV2/4 or AAV2/5; intravitreal injection of rAAV2/2 in dogs resulted in the detection of vector DNA along the visual pathway in the brain-the optic nerve, optic chiasm, optic tract, lateral geniculate nucleus, and visual cortex. These results suggested for the fi rst time the anterograde transport of rAAV2/2 from the retina to central visual structures.
Jacobson and colleagues (2006a,b) studied vector DNA distribution in the entire organism in dogs and primates at different time points after subretinal or intravitreal injection of AAV2/2 vector. They did not detect vector DNA in a dose escalation study of subretinally injected AAV2/2 in dogs (Jacobson et al. 2006a ), but temporarily detected it in the optic nerve and brain of primates 1 week after the animals received a subretinal injection of AAV2/2 vector (Jacobson et al. 2006b ). At 3 months after injection, only one primate had a detectable number of copies in the left geniculate nucleus. In all cases, although vector DNA was detected in the brain, there was no transgene expression in brain structures after subretinal injection. The explanation for this outcome may be a spreading of nonfunctional vector that does not allow transgene expression or transgene expression that was below detection level.
However, a recent study by our group reported the presence of vector DNA, GFP mRNA, and GFP protein in neurons in the left lateral geniculate nucleus (contralateral to the injected eye) after subretinal delivery in dogs (Stieger et al. 2008 ). In addition, we found vector DNA in many parts of the brain, but chiefl y on the contralateral side. These results demonstrated for the fi rst time that subretinal injection of AAV2/8 vector leads to gene transfer into distal parts of the brain. Because axons of the retinal ganglion cells project to the contralateral geniculate nucleus, the data also suggest trans-synaptic transport as the mode of delivery to these neurons; however, due to limitations in the experimental design, this could not be proved.
Preclinical Gene Therapy Studies in Nonhuman Primate Models of Retinal Degeneration
No inherited retinal disorders have been characterized in nonhuman primates, because homozygous animals for retinal degenerations would have a huge selective disadvantage in nature and would therefore not be able to survive and reproduce in the wild. Nevertheless, nonhuman primates represent an important model system to study retinal gene transfer because of their unique retinal structures, their equivalent size, and their human-like immune system (Table 1) .
sFLT-1 Gene Therapy to Treat Laser-Induced CNV For studies of the pathologic mechanisms of choroidal neovascularization, there are several large animal models, including pigs and nonhuman primates, in which laser-induced rupture of the Bruch's membrane produces lesions comparable to those in human patients (Ryan 1982; Saishin et al. 2003 Saishin et al. , 2005 . Using maximum energy levels of ophthalmic lasers, it is possible to cause lesions in the retina that lead to the development of new vessels that grow from the Bruch's membrane into the subretinal space. Generally, this technique is used to create up to eight small regional CNV lesions within or outside the retina in each treated eye (Shen et al. 2004 ). We will discuss only the nonhuman primate model of laser-induced CNV and its use in studies of antiangiogenic therapies based on AAV-mediated retinal gene transfer ).
As mentioned above, VEGF is the most important angiogenic factor in the pathogenic development of choroidal and retinal neovascularization in AMD and DR, respectively. It is produced by retinal cells and interacts with two receptors: VEGFR-1 (also known as FLT-1, fms-like tyrosine kinase; de Vries et al. 1992 ) and VEGFR-2 (or FLlk/Kbr, fetal liver kinase; Mustonen and Alitalo 1995) . Research has shown that an alternatively spliced isoform of VEGFR-1 (sFlt-1) is an inhibitor of VEGF activity (Kendall and Thomas 1993) and is responsible for corneal avascularity (Ambati et al. 2006 ). An improved understanding of the pathologic mechanisms of CNV has led to the development of new strategies for the treatment of this condition. One of these strategies involves the expression of antiangiogenic factors in the retina to block the activity of VEGF. Several antiangiogenic factors have been expressed in the retina of rodent models of laser-induced CNV: pigment epithelium-derived factor (Mori et al. 2002) , angiostatin (Lai et al. 2001) , and sFLT-1 (Lai et al. 2002) . Only the latter was the subject of study in a primate model of laser-induced CNV, in which the investigators subretinally injected an AAV2/2 vector carrying the sFLT-1 gene under the control of a CMV promoter in the central retina of three primates . The animals underwent laser-induced CNV 16 months later. The researchers found that new vessels, which normally start to grow into the ruptured site within 2 weeks, were signifi cantly less prominent and fl uorescein leakage was much lower in the treated eyes than in nontreated control retinas. The authors of the study concluded that this strategy could be a treatment option for patients with wet AMD, and a phase I clinical trial is in preparation.
Regulation of Transgene Expression
Antiangiogenic therapy restricted to the retina has been demonstrated in recent clinical trials using several synthetic anti-VEGF molecules. Injections are necessary every 1 or 2 months over several years, leading to anti-VEGF molecule levels in the retina that fl uctuate. AAV-mediated gene transfer protocols would allow the long-term expression of the molecules from within the retina, but it is not clear whether longterm near complete inhibition of VEGF is safe because this factor is important for endothelial cell survival and plays a role in the maintenance of blood vessels (Alon et al. 1995; Campochiaro 2007) . Also, circulation of anti-VEGF molecules derived from the retina may have negative effects on fenestrated capillaries in many endocrine glands and the gastrointestinal tract (Baffert et al. 2006; Kamba et al. 2006 ). In addition, VEGF provides survival signals for some neurons, such as the motor neurons in the spinal cord (Oosthuyse et al. 2001) . Whether VEGF plays a role in the maintenance of photoreceptors is unclear.
To avoid any unwanted side effects from long-term complete inhibition of VEGF, it is important to regulate the expression of antiangiogenic factors in a therapeutic window. Such an approach also enables the temporary suspension of anti-VEGF expression when necessary. The regulated expression of proteins is a further treatment option for retinal degeneration.
As mentioned above, inherited retinal degenerative disorders are triggered by mutations in a variety of genes, many of which have not yet been identifi ed. Hence, there is great interest in the development not only of a specifi c gene therapy but also of a more generally applicable survival factor therapy, which would not target the mutant gene but rather alter the photoreceptor environment in a manner that promotes cell survival.
To inhibit photoreceptor degeneration, neuroprotective factors have to be present in the retina for a long time, probably the life span of the individual. To avoid unwanted side effects, a regulatory system to control transgene expression could allow the expression of neuroprotective cytokines, such as ciliary neurotrophic factor (CNTF) and brainderived neurotrophic factor (BDNF), while abolishing their negative effects. Expression of these factors would be regulated in a therapeutic window. Of several regulatory systems tested in vitro and in vivo in mice, only two have advanced to evaluation in large animal models: small moleculedependent systems that use rapamycin or tetracycline as inducer drugs.
Rapamycin-Dependent System
The fi rst system used to regulate transgene expression in the retina of large animals is the rapamycin-dependent system. The basic concept of this approach is to express the two critical domains of a transcription factor as separate polypeptides that interact only in the presence of a dimerizer, such as rapamycin. In cells, rapamycin binds to two peptides, FKBP12 (FK506 binding protein of 12kDa) and FRAP (FKBP rapamycin-associated protein), bringing them into close proximity and thus activating their transcriptional competence as inhibitors of T cell proliferation and immunosuppression (Abraham 1998) . By fusing the FKBP12 domain to a DNA binding domain, called ZFHD1 (zinc fi nger homeodomain 1), and one portion of FRAP, called FRB (FKBP rapamycin binding), to the activation domain from the p65 subunit of transcription factor NF-kB, dimerization of both peptides would result in the formation of a functional transactivator. The FKBP12-ZFHD1 protein attaches to its corresponding binding domain upstream from the inducible promoter without activation of transgene expression. In the presence of rapamycin, the domain FRB-p65 affi xes to the FKBP12-ZFDH1 protein, resulting in the formation of the transactivator that allows the expression of the transgene; in the absence of rapamycin, the complex disintegrates into the two proteins, which are transcriptionally inert. The fi rst to describe such a system were Rivera and colleagues (1996) .
Initially, the rapamycin-dependent regulatory system served as a dual vector system in the retina (Auricchio et al. 2002 ). An AAV2/2 vector containing the FRB-p65 protein and the ZFHD1-FKBP protein, together with a second vector containing the recombinant human erythropoietine (EPO 1 ) gene under the control of the minimal interleukin (IL)-2 promoter fused to the ZFHD1 DNA binding site, were injected at a 1:1 ratio subretinally into rats and one nonhuman primate. Three days after an intraperitoneal administration of 2 mg/kg rapamycin, EPO concentration reached a peak (>100-fold induction) in the anterior chamber fl uid (a.c.f. 1 ) of the rats and returned to baseline levels within 21 days of rapamycin withdrawal. In the nonhuman primate, induction and deinduction kinetics were less tight, even though the serum half-life is 4½ hours, which would be an advantage for fast on and off switches. EPO concentrations peaked in the nonhuman primate's a.c.f. 1 to 2 weeks after drug delivery and dropped to baseline levels 44 days after drug withdrawal. The explanation for this delay in response to the change in drug application is not yet clear, but probably involves the strong stability of the transcription activating complex assembled by the drug.
Based on this study, Lebherz and colleagues (2005) conducted a 2-year study of rapamycin-controlled EPO expression in the retina of nonhuman primates. They injected the rapamycin-inducible dual vector system either intravitreally (n=1 animal) or subretinally (n=2 animals) at a 1:1 ratio in both eyes of each animal. Within 7 to 14 days of the intravenous administration, EPO levels reached a peak and returned to baseline levels within 3 to 4 weeks. Animals showed signs of weight loss but no other side effects after administration of 2 mg/kg of rapamycin. Lower doses of inducer drug resulted in lower EPO expression in the retina. No neutralizing antibodies against viral capsid proteins were detectable in serum or a.c.f., and histopathological examination of the retina showed only minor scar tissue at the injection site.
A limitation for the use of this system in clinical trials would be the challenge of simultaneously administering two vectors in a way that ensures they both transduce each cell in the retina. Cells transduced by only one of the vectors would not display regulated transgene expression but the continuous expression of the two chimeric regulatory proteins (FRAP-p65 or FKBP-ZFHD1). A second limitation is the pharmacology of rapamycin-bioavailability after oral administration is only 10%, requiring high doses for effective function. The third and most important limitation is the immunosuppressive activity of rapamycin, although there have been efforts to develop nonimmunosuppressive analogues ("rapalogs"), which carry substitutions at different positions in the protein chain (Chong et al. 2002; Pollock et al. 2002) . The less immunosuppressive rapamycin analogue AP22594 was tested in the primates used in the study by Lebherz and colleagues at equivalent doses to the original rapamycin, but induced EPO expression at levels only slightly above threshold values. This fi nding contrasts with results obtained with this analogue in a study done in the skeletal muscles of nonhuman primates, where it induced transgene expression effi ciently .
Tetracycline-Dependent System
The second system tested in large animal models is the tetracycline-dependent system. Regulatory systems based on this mechanism are widely used because they are able to tightly control transgene expression in a wide range of cultured cells as well as plants, yeast, insects, and mammals in vivo. They are based on the E. coli Tn10 tetracycline resistance operon, which consists of the tetracycline repressor protein (TetR) and the tetracycline operator DNA sequence (TetO) (Wissmann et al. 1986 ). In the absence of tetracycline or its derivate doxycycline (Dox), the TetR protein attaches to the TetO DNA sequence, whereas in the presence of the drug it changes its conformation, thus detaching from the DNA (Orth et al. 1998) .
Two different tetracycline-responsive regulatory systems have been developed based on this bacterial operon system; both contain the TetR protein fused to the transactivator VP16 of herpes simplex virus (HSV) (Gossen and Bujard 1992; Gossen et al. 1995) . If transgene expression is allowed only in the absence of Dox, the system is called TetOff; if it is allowed in the presence of Dox, the system is called TetOn.
The fi rst to evaluate tetracycline-dependent control of transgene expression in the retina were McGee Sanftner and colleagues (2001), who used a modifi ed TetOn system in the retina of rats. They observed successful induction and deinduction of GFP expression in response to the presence or absence of Dox in the drinking water. Oral administration of Dox at very low levels (2 µM) initiated GFP expression, which increased with the dose.
Folliot and colleagues (2003) also used an AAV vector to control transgene expression in the retina, with the TetOff system. Regulation of d2GFP expression was very tight, with 95% of retinal signal gone within 48 hours of Dox administration and 100% at 7 days. Upon Dox withdrawal, reexpression of d2GFP was slower, returning to full signal within 21 days, although it was readily detectable at 48 hours.
The use of tetracycline-dependent systems to drive reporter transgene expression in the eyes of higher mammals, such as nonhuman primates, is an absolute requirement before the initiation of any preclinical work on neuroprotective or antiangiogenic treatment of ocular diseases. Immune reactions against the reverse tetracycline-controlled transactivator (rtTA) in muscle-transduced primates raise particular concerns about the safety of this system (Favre et al. 2001) . However, the eye has developed some special features to prevent ocular infl ammation, a pathologic mechanism that is incompatible with good vision; the eye's anatomical, cellular, and molecular specializations are together referred to as "ocular immune privilege" (for review see Streilein 2003) . Therefore, in contrast to the muscle, local immune modulation in the eye allows rtTA-mediated transgene regulation in the eye of higher mammals.
Our group developed a regulatory system based on the TetOn technique that controls the expression of EPO in the eye of nonhuman primates (Stieger et al. 2006 . The use of EPO as a reporter protein allows easy and objective quantifi cation of transgene expression in the a.c.f. and thus represents an advantage over the subjective evaluation of GFP expression. We injected three different vectors-AAV2/5.CMV.TetOn.epo, AAV2/4.CMV.TetOn.epo, and AAV2/4.pRPE65.TetOn.epo-in seven primates. Induction of EPO expression was performed initially by 3-day Dox pulses given intravenously (10 mg/kg/day). EPO concentrations reached a peak 2 to 4 days after Dox administration and declined to background levels 10 to 14 days after withdrawal of the inducer drug. Maximum EPO concentrations in the a.c.f. were 1000 mU/ml (for animals injected with the AAV2/5.CMV.TetOn.epo vector), 100 mU/ml (AAV2/4. CMV.TetOn.epo), and 10 mU/ml (AAV2/4.pRPE65.TetOn. epo). These results represent a 2 log range of possible concentrations for any given therapeutic protein, depending on the serotype injected, the amount of vector injected, and the promoter driving the expression of the rtTA protein. Regulated transgene expression persisted for more than 4 years with no immune response to either the expression of both rtTA and EPO proteins or the AAV vectors. Because the possibility of oral administration of Dox is a key factor when considering advancing to clinical trials, we also evaluated the infl uence of oral administration on the capacity to control transgene expression . In this study, we demonstrated not only the similarly effi cient and tight control of induction and deinduction of EPO expression after oral administration of Dox but also the system's ability to continuously induce transgene expression for 6 months without any negative side effects.
Based on these extensive preclinical experiments in nonhuman primates, we conclude that this regulatory system is a useful tool in the development of neurotrophic or antiangiogenic gene therapy strategies for the retina.
Preclinical Gene Therapy Studies in Canine Models of Retinal Degeneration
Inherited retinal dystrophies are common among many breeds in the canine population, and the most common form is progressive retinal atrophy (PRA). Veterinary opthalmologists have identifi ed several subgroups of the disease, depending on whether the photoreceptors have fully developed (dystrophies) or not (dysplasias) before degeneration, and whether inheritance is autosomal recessive, autosomal dominant, or X-chromosomal (Petersen-Jones 2005) . In addition, researchers have described inherited retinal dystrophies in several feline breeds (Narfström 1999) and have developed transgenic pigs (Petters et al. 1997) .
A limited number of dog breeds with retinal degenerations have served as large animal models for human retinal diseases and been thoroughly studied for the development of gene-based therapies. Of these, the Swedish Briard (RPE65 −/− ) is the only dog breed that has responded successfully to gene therapy, opening the door for several human clinical trials (see below). Soon, the two dog breeds with mutations in the CNGB3 gene (the Alaskan malamute and the German shorthaired pointer), which represent a canine model for human achromatopsia, may follow suit.
Other canine models, which we present in detail below, have not yet been used in gene therapy protocols but are considered ideal models for such studies. They have been well characterized, on both the clinical and molecular level, and transgenic mouse models for the complementary human diseases have responded successfully to gene therapy, which is a prerequisite for such trials in dogs.
Successful Gene Therapy Studies
Canine Model for Autosomal Recessive RP, LCA Due to a Mutation in the RPE65 Gene: Translation to Human Trials
The RPE65 gene encodes for an RPE-specifi c 65 kD protein that is the isomerohydrolase in the visual cycle, restoring the rhodopsin ligand 11-cis retinal. Mutations in this gene are responsible for about 6% of all LCA cases. In addition to a genetically engineered RPE65 knockout mouse model (Redmond et al. 1998) , there are two naturally occurring models of LCA caused by mutations in RPE65: the homozygous Swedish Briard dog (Aguirre et al. 1998 ) and the rd12 mouse (Pang et al. 2005) . Like humans, these animals do not develop suffi cient amounts of the photopigment rhodopsin, and as a result have poor vision and diminished light-and dark-adapted ERG responses. The Briard represents an especially valuable model for the development of a gene therapy for RPE65-defi cient patients, as the phenotype of the retinal degeneration is very similar to that of humans (Table 2) . In these animals, a 4 bp deletion leads to a premature stop codon and the absence of functional protein in the retina (Veske et al. 1999) .
Two research groups demonstrated that a single subretinal injection of an rAAV2/2 vector carrying the canine RPE65 gene under the control of a strong chicken/beta-actin (CBA) promoter was suffi cient to restore visual function in these animals, as assessed by ERG, immunochemistry, and behavioral testing Narfström et al. 2003) , and they reported the long-term outcome of their studies Narfström et al. 2005 ). Acland and colleagues (2005) injected several different constructs-using AAV2/1, 2/2, or 2/5 capsids, the nonspecifi c CMV promoter, or the tissue-specifi c RPE65 promoter to drive either the canine or the human RPE65 gene-and reported restoration of visual function for up to 3 years. Narfström and colleagues (2005) also studied the long-term outcome of their animals, which received AAV2/2.CMV.cRPE65 injections, and reported a gradual loss of visual function as measured by ERG over 3 years; the reason for the loss was not clear.
In view of a possible human gene therapy trial, Bennicelli and colleagues developed an AAV2/2 vector carrying the human RPE65 gene under the control of a modifi ed CBA promoter and tested this vector successfully in the canine model . Based on these data, a phase I/II clinical trial began in 2007 (www.wiley.co.uk/genmed/clinical; Trial ID US-740, A. Maguire) and the fi rst encouraging results of the treatment of three patients have been published recently ). The most important goal of the initial study was safety and none of the patients developed any severe adverse reaction to the treatment. A second group, led by Jacobson and Hauswirth, reported preclinical safety data on 18 RPE65 −/− dogs and 17 normal nonhuman primates received subretinal injections of an rAAV2/2 vector carrying the human RPE65 gene driven by the CMV/beta-actin hybrid promoter (Jacobson et al. 2006a,b) . These studies provided the data for preparation of a phase I/II clinical trial, the results of which have not been published yet (www.wiley.co.uk/genmed/clinical; Trial ID US-677, S. Jacobson).
Our group in Nantes has recently demonstrated the capacity of a rAAV2/4 vector carrying the human RPE65 gene under control of the human RPE65 promoter to restore vision in the Briard dog (Le ). As mentioned above, rAAV2/4 vectors transduce only the RPE and therefore the use of this serotype increases the specifi city and safety of the therapy. In addition, the tissue-specifi c RPE65 promoter also increases specifi city by allowing physiologic transgene expression only in RPE cells. We are preparing a clinical phase I/II trial for the treatment of RPE65 patients in France that may start in 2010.
In addition to the rAAV2/4 vector, we tested an AAV2/2 vector carrying the same expression cassette side by side in RPE65 −/− dogs (Le ). Based on these results, a group led by Robin Ali at the Moorfi elds Eye Hospital (London, UK) began in 2007 a phase I/II clinical trial for the treatment of RPE65 −/− patients using a rAAV2/2 vector carrying the human RPE65 gene driven by the human RPE65 promoter for subretinal injection (www.wiley.co.uk/genmed/ clinical; Trial ID UK-141, R. Ali). The results of this trial were recently published ). Again, safety was the most important goal of the study and none of the three patients developed any severe adverse effect.
The RPE65 clinical trials are to date the only realistic treatment option for patients with retinal degenerative diseases, but mutations in this gene are extremely rare. In contrast, more than 180 gene loci have been identifi ed, and each requires the development of a separate gene therapy protocol. The successful story of the RPE65 gene therapy strategy-from the initial identifi cation in 1997 of patients with this mutation (Gu et al. 1997) , to the identifi cation in 1998 of dogs carrying a similar mutation (Aguirre et al. 1998) , to the fi rst successful gene therapy experiments in these dogs in 2001 , and up to the start of the fi rst clinical trials in humans in 2007 Maguire et al. 2008 )-highlights the need for large animal models of inherited degenerative diseases for the development of new therapeutic strategies.
Canine Models of Achromatopsia (CNGB3)
Achromatopsia is an autosomal recessive inherited disorder that affects photoreceptor cells. It has been associated in dogs with a substitution in exon 6 (D262N) of the CNGB3 gene in German shorthaired pointers and with a nonsense mutation in Alaskan malamutes Sidjanin et al. 2002) (Table 2) .
In humans, mutations in three different genes are associated with this disease: CNGA3, CNGB3, and GNAT2. CNGB3 encodes for the beta-subunits of cyclic nucleotide-gated channels in the photoreceptor plasma membrane, and mutations in the gene cause a channelopathy that results in impaired cone function manifesting achromatopsia (Khan et al. 2007 ). Mutations in the CNGB3 gene are responsible for 50% of all cases of human achromatopsia (Kohl et al. 2005) .
In humans and dogs, affected subjects show an absence of retinal cone function with colorblindness, day blindness, and photophobia, but normal vision in dim light. Progressive retinal atrophy has been described in 1974 by Aguirre and colleagues in the Alaskan malamute, and in 2006 by Beltran and colleagues in the German shorthaired pointer. In both canine models, cone response was abolished at the age of 8 weeks Rubin 1974, 1975; Beltran et al. 2006) , and by adulthood the retinas lack all cones (although the structure and function of rods remain normal). Potential rAAV gene therapy treatment for achromatopsia must therefore target cones.
Komaromy and colleagues (2008a) evaluated three versions of the human red cone opsin promoter (PRO.5, 3LCR-PRO.5, PR2.1) and the human blue cone opsin promoter (HB569) for their specifi city in targeting GFP gene expression to cones in the canine retina when used with AAV vectors of serotype 5. After subretinal injection, the blue cone opsin promoter (HB569) was not specifi c, because GFP was expressed in a few cones but also in some rods and the retinal pigment epithelium. The PRO.5 promoter was not at all effective and the modifi ed version of this promoter, the 3LCR-PRO.5, led to weak GFP expression in cones. Only the PR2.1 promoter led to effective and specifi c transgene expression in cones (Komaromy et al. 2008a) .
Based on these studies, affected dogs received unilateral injections in the subretinal space with an AAV2/5 vector containing the transgene CNGB3 under the control of these four different promoters (PRO.5, 3LCR-PRO.5, PR2.1, and the human cone arrestin promoter). Four weeks after treatment, 10 dogs with either CNGB3 null or missense mutation showed successful restoration of cone function. Animals that received treatment at a young age experienced the best outcome. Although all four promoters yielded positive results, the PR2.1 promoter produced the most robust restoration of cone function. Monitoring for over 14 months of two dogs treated with AAV5.PR2.1.CNGB3 revealed no deterioration of the rescue effect (Komaromy et al. 2008b ).
Other Canine Models of Retinal Degeneration as Possible Candidates for Gene Therapy
Autosomal Recessive RP (PDE)
Rod-cone dysplasia 1 (rcd1) is a photoreceptor pathology in dogs that resembles the pathologic features of autosomal recessive RP due to mutations in the rod-specifi c cGMP phosphodiesterase (PDE) and segregates in the Irish setter breed (Table 2) .
Dogs affected with rcd1 display markedly elevated levels and abnormal distribution of PDE activity. Farber and colleagues (1992) suggested that the beta subunit is implicated in the disease, and Suber and colleagues (1993) went on to identify a nonsense mutation at codon 807, introducing a premature stop codon, which truncates the protein by 49 residues; the mutation removes the C-terminal domain necessary for post-translational processing and membrane association.
In humans, there are several mutations in the PDE-β gene that lead to autosomal recessive RP, accounting for 4% of cases in North America. Characteristic of these patients are reduced, delayed, or nonexistent rod ERG responses, markedly reduced cone responses, and a lack of night vision beginning in early childhood. Ophthalmoscopy reveals attenuated retinal vessels (Dryja et al. 1999; McLaughlin et al. 1993 McLaughlin et al. , 1995 .
In Irish setters, the photoreceptor degeneration begins approximately 25 days after birth and culminates at about 1 year of age, when the population of rods and cones is completely depleted. A pharmacological study showed that Dcis-diltiazem, a calcium channel blocker used in cardiology, rescued photoreceptors and preserved visual function in the rd mouse, a rodent model of PDE-β mutations (Frasson et al. 1999) . But use of the same protocol for the rcd1 Irish setters was not successful: D-cis-diltiazem did not slow their retinal degeneration .
Although this dog model was discovered 16 years ago, it is diffi cult to develop a treatment because of the rapid evolution of the lesions. Gene therapy with this model is very challenging because the therapeutic window is very narrow and because photoreceptor defects are more diffi cult to treat than RPE defects after retinal gene transfer.
Autosomal Recessive LCA (RPGRIP1)
Defects in the retinitis pigmentosa GTPase regulator interacting protein 1 (RPGRIP1) gene cause an autosomal recessive disease affecting photoreceptor cells in dogs and humans.
Researchers have recently identifi ed the RPGRIP1 mutation involved in the miniature longhaired dachshund (MLHD) (Mellersh et al. 2006) (Table 2) ; it consists of a 44 bp insertion in exon 2 of the RPGRIP1 gene, introducing a premature stop codon. The RPGRIP1 protein was discovered through its interaction with RPGR (retinitis pigmentosa GTPase regulator) (Boylan and Wright 2000) . The function of RPGR and RPGRIP1 are not fully understood. Both proteins localize in the photoreceptor connecting cilium, a thin bridge linking the cell body and the light-sensing outer segment. A study of RPGRIP1 −/− mice demonstrated that RPGRIP1 is a stable polymer anchored to the axoneme of the connecting cilium where it tethers RPGR and that RPGR itself depends on RPGRIP1 for subcellular localization and normal function . Both proteins may be involved in microtubule organization in the connecting cilium and regulation of molecular traffi cking between the inner and outer segments of photoreceptors (He et al. 2008) . Another study suggested that RPGRIP1 is required for disk morphogenesis, putatively by regulating actin cytoskeleton dynamics (Zhao et al. 2003) . Experiments in mice identifi ed intense alternative splicing of the RPGRIP1 gene, which led to several mRNA variants with distinct cellular and subcellular localization between species (Castagnet et al. 2003; Mavlyutov et al. 2002) .
The human RPGRIP1 gene is localized on chromosome 14q11 and contains 3861 base pairs divided in 24 exons (Gerber et al. 2001) . Several studies reporting a comprehensive mutational analysis of all known genes in 179 unrelated patients showed that mutations in RPGRIP1 account for 4.5% of the cases (Dryja et al. 2001; Hanein et al. 2004; Meindl et al. 1996) . Clinical signs include photophobia, severe loss of central acuity, and nystagmus.
In order to evaluate the canine RPGRIP1 −/− dog model as a potential candidate for gene therapy, two groups have now characterized the kinetics and pathological mechanisms of the retinal degeneration (Rolling, unpublished data; Turney et al. 2007 ). Analysis of the ERG fi ndings showed that cone function was lost as early as 2 months of age, although the cone photoreceptors were still present in the retina, and rod function was preserved. But at 9 months of age, both cone and rod functions were undetectable. Interestingly, assessment of the dogs' functional vision, based on their ability to avoid obstacles, showed that it remained up to the age of 11 months. Both optical coherence tomography (OCT) and histopathology studies revealed a progressive thinning of the neuroretina over the fi rst 2 years of age. The TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assay showed that the apoptotic photoreceptor cell death was the causative mechanism (Rolling, unpublished data).
The results of the study by our group suggest a therapeutic strategy that consists of initiating gene therapy as soon as possible after birth. The RPGRIP1 −/− dogs represent a unique and important tool to assess the in vivo effi cacy of photoreceptor targeted gene therapy in a cone-rod dystrophy. However, visual function in this canine model will still be diffi cult to rescue using gene therapy because (1) the photoreceptors and not the RPE need to be targeted, (2) RPGRIP1 is a structural gene, and (3) variants of the gene might be expressed and functional not only in photoreceptors but also in other retinal cell types (Castagnet et al. 2003; Mavlyutov et al. 2002; Zhao et al. 2003) .
X-Linked RP (RPGR)
The X-linked progressive retinal atrophy (XLPRA) in dogs is similar to human X-linked RP and is also caused by mutations in the RPGR gene. Two mutations in exon ORF15 occur in three canine models: a 2 bp deletion in Siberian huskies and Samoyeds (XLPRA1), and a 5 bp deletion in mongrel dogs (XLPRA2) (Zhang et al. 2002) (Table 2) .
Studies in mice have localized the RPGR protein to the connecting cilium of both photoreceptor types, rods and cones . The fi rst 10 exons encode a tandem repeat structure highly similar to RCC1 (regulator of chromosome condensation), which suggests an interaction with a small GTPase. This RCC1-like domain is present in all major isoforms of RPGR. The most important function of RPGR seems to be the interaction with the RPGRIP1 protein (as described above); it is also involved in microtubule organization and regulation of molecular traffi cking in the cilia of the photoreceptor (located between the inner and outer segments) (He et al. 2008 ). In addition, the protein associates with a number of cilia-centrosomal proteins (e.g., structural maintenance of chromosomes [SMC] 1 and SMC3) as well as with the intrafl agellar transport polypeptide IFT88 and microtubule motors such as Kif3A-KinesinII (Khanna et al. 2005) .
The considerable heterogeneity in RPGR transcript processing results from an alternative RNA splicing mediated by multiple purine-rich exonic splicing enhancers (Hong and Li 2002) . Of the many isoforms expressed in the retina, RPGR-ORF15 is the major form, containing the fi rst 14 exons of the gene plus an unusually large terminal exon ORF15 (Vervoort et al. 2000) . About 80% of the more than 240 identifi ed disease-causing mutations in this gene occur in a specifi c repetitive region of the ORF15 (which is thus called the "mutation hot spot" of RPGR).
XLRP represents the most severe form of RP in humans, with early onset of night blindness, visual fi eld loss, and eventual loss of central acuity. In dogs, the phenotype associated with the frame shift mutation in XLPRA2 is very severe and manifests during retinal development (Beltran et al. 2006) . In contrast, the phenotype associated with the nonsense mutation in XLPRA1 manifests after normal photoreceptor morphogenesis. Morphological characterization has shown that photoreceptor cells develop and function normally, but subsequently undergo a progressive degeneration with variability in onset and severity. Rods are affected fi rst, and cone degeneration starts later (Zeiss et al. 1999) . Abnormal development of photoreceptors was evident in XLPRA2 dogs as early as 4 weeks of age (Beltran et al. 2006) , whereas in XLPRA1 dogs photoreceptor degeneration was present at 4 to 5 years of age (Guyon et al. 2007 ). The normal retinal development in XLPRA1 suggests that the C-terminal 230 amino acids encoded by exon ORF15 are not crucial for functional and structural development of rods and cones early in life, but the severity of the disease at later stages demonstrates that RPGR plays an essential role in photoreceptor viability (Zhang et al. 2002) .
Siberian huskies (XLPRA1) provide a particularly valuable model to evaluate gene therapy because both their genetic mutation and clinical characteristics are comparable to those of humans. In addition, because the onset of the lesions occurs later and the evolution is slower in XLPRA1 dogs than in XLPRA2 dogs, the window for therapeutic treatment is larger. The therapeutic hurdles for the rescue of visual function in this canine model are similar to those for RPGRIP1 −/− dogs, because (1) the source of the problem is a photoreceptor defect and (2) the RPGR gene undergoes complex alternative splicing and encodes multiple protein isoforms (constitutive and ORF15 variants).
Autosomal Dominant RP (RHO)
More than 100 different mutations in the rhodopsin gene (RHO) cause autosomal dominant retinitis pigmentosa (ADRP) in humans. Kijas and colleagues (2002) described English mastiffs with a naturally occurring dominant retinal degeneration and identifi ed a disease-causing point mutation in the RHO gene (T4R) ( Table 2) .
Rhodopsin is the G protein-coupled receptor that is activated by light and initiates the transduction cascade that enables night vision. Mutations in the rhodopsin gene account for most cases of ADRP, but the RHO group of diseases includes a variation of severity that is not strictly mutation dependent-there are differences within and between families and even within regions in the same affected eye Gu et al. 2007 ). The hypothesis is that genetic background and environmental factors (e.g., light) can modify the phenotype.
Dogs with the mutant allele manifest a retinal phenotype that closely mimics the human phenotype of RHO mutations. The T4R RHO-mutant dog retina shows a dramatically slowed recovery of rod photoreceptor function after light exposure. There seems to be a link between the mutant-RHO retina's level of exposure to light and the photoreceptor cell death.
The English mastiffs are a valuable canine model for gene therapy trials because their mutations and phenotypes are very similar to those of humans and because RHO mutations are a very common cause of ADRP, affecting a large pool of potential human patients. But simple gene addition therapy in this dominant canine model may not be suffi cient to rescue the photoreceptors, as the expression of the mutant allele is toxic to these cells. Because the presence of only one mutant allele is suffi cient for the onset of retinal degeneration in dominant diseases, gene suppression in conjunction with gene addition is necessary. To downregulate the production of toxic proteins in the cell, several strategies are now available, including one that calls for the use of ribozymes and another the use of siRNA (small interfering ribonucleic acid) technologies; both strategies have been studied in rodent models of the disease with varying degrees of success. Subretinal administration of an rAAV containing siRNA that downregulates both endogenous alleles of rhodopsin while expressing a normal protein from a transgene has been a promising strategy in mice (O'Reilly et al. 2007 ).
To our knowledge, there have been no tests of this or any other gene therapy-based strategy in the canine T4R model. The major hurdles for the development of such strategies are the targeting of photoreceptors, and, more importantly, the effi cient suppression of endogenous RHO expression and effi cient gene replacement in the same photoreceptor cell.
Best Disease (VMD2)
Canine multifocal retinopathy (cmr) is caused by mutations in the bestrophin gene (BEST1, also called VMD2). Although dogs lack a foveomacular region, the ophthalmoscopic appearance of lesions characteristic of cmr closely resembles vitelliform lesions in the human counterpart, Best macular dystrophy.
Cmr occurs in several dog breeds, two of which have been studied in detail: Great Pyrenees (cmr1) and Coton de Tulear (cmr2). The disease is inherited as an autosomal recessive condition (Guziewicz et al. 2007 ) and is associated in Great Pyrenees dogs with a C73T stop mutation and in Coton de Tulear dogs with a G482A missense mutation.
Cmr1 in Great Pyrenees dogs was fi rst described by Grahn and colleagues in 1998, and is manifested by multifocal serous retinal and RPE detachments. The condition develops at approximately 13 weeks of age and the focal areas of retinal detachment and RPE vacuolation progress to permanent and stable focal areas of retinal degeneration, RPE hypertrophy, and changes in RPE pigmentation. ERG measurements did not reveal signifi cant deterioration of the a-or b-wave parameters (Grahn and Cullen 2001; Grahn et al. 1998) .
Cmr2 in the Coton de Tulear manifests as multifocal serous retinal detachments in homozygous puppies at 3 to 4 months of age. The retinopathy occurs early in life and is nonprogressive. Photopic and scotopic ERG measurements are minimally diminished compared to age-matched dogs that do not carry the mutation (Grahn et al. 2006 (Grahn et al. , 2008 .
Best macular dystrophy in humans is an autosomal dominant retinal disease caused by mutations in the bestrophin gene. It is typically characterized by a single vitelliform lesion of the macula that is yellow to orange and appears in childhood. However, phenotypic heterogeneity occurs, and multifocal vitelliform, atrophic lesions, or chorioretinal scars have been described. The disease is slowly progressive and can result in atrophy of the RPE, photoreceptor degeneration, and subretinal fi brosis, severely impairing central vision (Guziewicz et al. 2007 ).
The human VMD2 gene is located on the long arm of the human chromosome 11. Bestrophin is a transmembrane protein localized at the basolateral portion of the RPE; its function is not fully understood. One hypothesis is that it functions as a regulatory part of a calcium-dependent channel; a second hypothesis is that it regulates a voltage-dependent Ca 2+ channel assuming an indirect involvement of bestrophin in the generation of the light peak in the ERG (Strauss and Rosenthal 2005) . The pathogenicity of VMD2 mutations is likely based on a dominant negative effect possibly by oligomerization of normal and mutated bestrophin molecules to form a defective ion channel (Stohr et al. 2005) .
To assess a potential rAAV-mediated gene therapy for cmr in affected dogs, Zangerl and colleagues (2008) evaluated the human bestrophin promoter (hVMD2) for its specifi city in targeting GFP expression to RPE cells in the canine retina using an AAV2/1 vector. Four weeks after subretinal injection in normal dogs, GFP expression was evident in RPE cells in the injected area. Based on these preliminary results, the authors are evaluating rAAV-mediated expression of wild-type bestrophin in place of GFP in the same construct in order to treat affected dogs. The results of these trials have not yet been published.
Conclusion
Two large animal systems are used in the development of gene therapy strategies for retinal disorders, nonhuman primate and canine models of retinal degenerations. Nonhuman primates are essential for any treatment strategy, as the animals' retinal structure and other close similarities with human physiology enable researchers to obtain the most reliable safety information without risking potentially severe negative side effects in human clinical trials. Moreover, the human-like immune system of nonhuman primates allows the evaluation of possible adverse immune responses to vector or transgene. Biosafety studies with primates are now a requirement before initiation of any clinical trials for retinal gene therapy. However, because there is no pathologic model for inherited retinal dystrophies in nonhuman primates, these animals are of limited use in the evaluation of the therapeutic benefi t of a given treatment strategy.
In contrast, many human genetic diseases have their equivalent in the canine population. Once descendants of the wolf became domesticated, natural selective pressure, which normally eliminates disadvantageous mutations, no longer applied. In this review we have described canine models that have been thoroughly characterized and are in use today for the development of gene therapy strategies. Canine models of retinal degenerations exist for all major inheritance patterns, including autosomal recessive (RPE65, RPGRIP1), autosomal dominant (RHO), and X-linked (RPGR) PRA. Mutations in RHO and RPGR account for 25% of all ADRP and 70% of all XLRP cases in humans, respectively. Therefore, the canine models for these diseases can support the development of treatment strategies for many patients around the world. Recently, proof of principle in the Briard RPE65 dog model led to the start of three clinical trials of gene therapy for inherited retinal degeneration. New forms of canine retinal degeneration that await characterization may represent additional valuable models for retinal gene therapy.
The successful treatment of canine models in gene therapy protocols is essential for any research group that plans to advance its fi ndings to clinical trials. These models are very important to support the development of treatment strategies for diseases for which no treatment option is yet available.
